"10.1371_journal.pone.0144121","plos one","2016-01-25T00:00:00Z","Aaltje Y Adema; Frans J van Ittersum; Joost G Hoenderop; Martin H de Borst; Prabath W Nanayakkara; Piet M Ter Wee; Annemieke C Heijboer; Marc G Vervloet; NIGRAM consortium","Department of Nephrology, VU University Medical Center, Amsterdam, The Netherlands; Department of Physiology, Radboud university medical center Nijmegen, The Netherlands; Department of Internal Medicine, Division of Nephrology, University Medical Center Groningen, Groningen, The Netherlands; Department of Internal Medicine, VU University Medical Center, Amsterdam, The Netherlands; Department of Clinical Chemistry, VU University Medical Center, Amsterdam, The Netherlands; Institute for Cardiovascular Research VU (ICaR-VU), Amsterdam. The Netherlands","Conceived and designed the experiments: AA PMTW MGV. Analyzed the data: AA FJvI JGH MHdB MGV. Contributed reagents/materials/analysis tools: PWN ACH. Wrote the paper: AA FJvI MHdB MGV.","The authors have the following interests: Co-author Dr. Marc G. Vervloet received research support from Fresenius, Shire, Sanofi, AbbVi and Amgen. Dr. Marc G. Vervloet also received speakers fees from Baxter and Amgen and served as consultant for Astellas, Amgen, Fresenius and AbbVie. All other authors declare that no competing interests exist. There are no patents, products in development or marketed products to declare. This does not alter the authors adherence to all the PLOS ONE policies on sharing data and materials, as detailed online in the guide for authors.","2016","01","Aaltje Y Adema","AYA",9,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA
